ABSTRACT. Eleven patients with methylmalonic aciduria
mutase are distinguishable by detailed enzymologic studies and by complementation studies in cultured skin fibroblasts: mutase deficiencies are classified as muto (no mutase activity under saturating cofactor concentrations) and mut-(some residual activity) and other disorders involving cobalamin defects as Cbl mutants [Cbl A (mitochondrial reductase deficiency), Cbl B (deoxyadenosyltransferase deficiency), Cbl F (defective lysosomal release of OHCbl), and Cbl C and D (defective cytosolic reductase, associated with homocystinuria)].
Some patients with cobalamin defects may respond biochemically and clinically to pharmacologic doses of vitamin B12 (OHCbl), with more than 90% of Cbl A patients showing a marked response and a subsequent favorable clinical course (6) . However, fewer than 40% of Cbl B patients respond to B12 therapy and show a relatively poor clinical course. The reasons for the variable responses in the latter group of patients are unclear and illustrate the heterogeneity of the disorder. Most patients with methylmalonic aciduria have been treated with OHCbl, although one or two patients have received AdoCbl.
Batshaw et al. (7) reported an unsuccessful response to adenosylcobalamin therapy in a Cbl B patient, but more recently Bhatt et al. (8) reported briefly that a patient unresponsive to OHCbl had shown an improvement during adenosylcobalamin therapy. The latter patient was not, however, clearly classified, although plasma cobalamin analysis showed complete absence of adenosylcobalamin before therapy.
We report here detailed enzymologic studies on cultured skin fibroblasts from 1 1 patients with methylmalonic aciduria that permitted subdivision in accord with the conventional complementation groups: Results from one cell line suggested that the patient concerned had adenosyltransferase deficiency and might respond in vivo to AdoCbl therapy. Results of a therapeutic trial of AdoCbl are reported together with further studies on the patient's cells in culture. Our results suggest that the cofactor is unable to enter the cells in an unchanged form, and we conclude that adenosylcobalamin therapy offers no advantages over OHCbl therapy for the treatment of patients with methylmalonic aciduria. We suggest that Cbl B patients who respond to OHCbl therapy have a different molecular defect from that in unresponsive patients. These results have been reported in brief abstract form elsewhere (9) . Studies were approved where appropriate by the Harrow Health District Ethical Committee.
PATIENTS AND METHODS
Patients. Eleven patients with isolated methylmalonic aciduria were studied. All had been diagnosed using gas chromatographymass spectrometry on the basis of methylmalonic aciduria (and associated abnormal organic aciduria including methylcitrate diastereoisomer excretion), without homocystinuria, and by enzymology on cultured skin fibroblasts based upon incorporation of [l-14C] (10) . One of the mut0 patients and patient 1 1 were described by Bain et al. (10) in reference to metronidazole therapy. The OHCbl-responsive patient is maintained solely on oral OHCbl and is alive and well at age 15 y.
Case report. The patient of particular interest in the present study (patient 11) was a girl who originally presented with recurrent vomiting and failure to thrive in the 1st month of life. She was diagnosed with methylmalonic aciduria at the age of 6 mo and, being unresponsive to OHCbl therapy, was treated with a low-protein diet supplemented with amino acids, vitamins, and minerals. She has had repeated admissions to hospital but, although initial development was slow, she now attends a normal school and is making relatively good progress, despite continuing dietary problems and reduced renal function. She showed some clinical improvement on L-carnitine and has recently shown marked improvement on metronidazole therapy, with improved appetite, behavior, and general well-being; she is maintained on her dietary restriction, L-carnitine and metronidazole.
Methods. Skin fibroblasts were cultured in Eagle's minimum essential medium (no Biz) with 10% FCS, nonessential amino acids, penicillin, and streptomycin. Cells were harvested with trypsinization and washed with PBS before further study as described below. All additions of cobalamins and cell culture with added cobalamin were camed out in the dark. All cell lines studied were free from mycoplasma contamination.
Propionate incorporation in intact cells was measured by seeding cells into 25-cm2 Falcon flasks and subculturing for 3 d in minimum essential medium as above; cells were washed with PBS and incubated at 37°C for 18 h in PBS containing 15% FCS, 0.2% glucose, and 2 pCi/l pmol [l-'4C]propionate. Incorporation of [1,4-'4C]succinate was measured as control. The cell monolayer was fixed at the end of the incubation by removing the medium, adding 1 mL 10% trichloroacetic acid solution, and incubating in the cold for 0.5 h. The trichloroacetate was removed, and the cell layer washed twice with PBS and then dried at 37°C. The cell monolayer was dissolved in 1.0 mL 2% Na2C03 in 0.1 M NaOH, and the radioactivity in the solution was determined by liquid scintillation counting. Protein content was determined using a modified Lowry assay, and the results were expressed as pmol substrate incorporated/mg proteinlh. Incorporation was measured with and without added OHCbl.
Methylmalonyl CoA mutase activity was measured directly on cell sonicates in the presence of 5'-AdoCbl by measurement of the incorporation of [methyl-'4C]methylmalonyl CoA into succinyl CoA. Cell sonicates were incubated at pH 7.4 for 30 min to 1 h with 12.9 nCi/36 nmol methylmalonyl CoA and the reaction was stopped and CoA esters were hydrolyzed by addition of 5 mmol/L KOH and incubation at 37°C for 15 min. Unlabeled (carrier) methylmalonate and succinate were added, followed by acidification with 5 mol/L HC1O4. The mixture was chilled, and potassium perchlorate, protein, and particulate matter were removed by centrifugation to produce a clear supernatant. Methylmalonate and succinate were separated by reversed phase HPLC using a Varian 5000 HPLC equipped with a multidiode array detector (Hewlett-Packard Co., Palo Alto, CA) operated at 2 10 nm, on a MOS-Hypersil 5-pm (C8) 20 cm x 2.1 mm inner diameter column (Hewlett-Packard) fitted with a guard column, using 0.05 M phosphoric acid containing 1 % methanol as solvent (flow rate 200 pL/min). Succinate and methylmalonate eluted within 4-7 min; radioactivity was determined in collected 90-pL fractions, and the results were plotted and combined for the appropriate peaks. Final results are expressed as nmol succinate (succinyl CoA) producedlmg proteinlh.
Control fibroblast lines were obtained from the National Institute of General Medical Sciences Human Genetic Mutant Cell Respository, Camden, NJ, and from local children without demonstrable genetic disease undergoing minor surgical operations. They were selected to match the age range of the patients concerned (cell lines GM 302, GM 409, GM497, GM 500, GM969, and GM 970; age range 3 d to 10 y).
Plasma and erythrocyte cobalamins were measured using previously published procedures (1 I), and the patient's biochemical response to the treatment was monitored by measurement of urinary organic acids determined using capillary gas-liquid chromatography of diethylaminoethyl Sephadex extracts (1 2).
RESULTS
In vitro enzymology. Eight of the cell lines studied (patients [1] [2] [3] [4] [5] [6] [7] [8] showed no detectable activity of methylmalonyl CoA mutase when assayed in the presence of saturating concentrations of 5'-AdoCbl and were classified as mut0 variants. One cell line (from patient 9) showed some residual activity under these conditions and was classified as a mut-variant. Cells from patient 10, who was responsive to OHCbl in vivo, showed normal activity under these conditions, as did cells from patient 1 1 (Table 1) . Cells from both of the latter patients showed increasing mutase activity as adenosylcobalamin concentrations were increased.
Propionate incorporation in intact cells was minimal under basal conditions in all cell lines. Cells from patient 10 showed increasing levels of propionate incorporation in intact cells cultured in the presence of increasing concentrations of OHCbl (Table 2) , consistent with his responsiveness in vivo. Patient 10 was assumed from these results to have a Cbl A mutation affecting mitochondria1 cobalamin reduction with normal deoxyadenosyltransferase activity, inasmuch as his cells were clearly able to convert added OHCbl into adenosylcobalamin to restore mutase activity. However, cells from patient 1 1 (and mut0 pa- The responsiveness of her cell sonicates to AdoCbl suggested that she might benefit from AdoCbl therapy.
Clinical trial of deoxyadenosylcobalamin in patient 11 . The therapeutic trial of AdoCbl was camed out in hospital. Informed consent was obtained from her parents before the trial. Two d after admission, she was given 4 mg AdoCbl (Cobanzyme; SAS Pharmaceuticals, Beaconsfield, UK) i.v. followed by a further 4 mg intramuscularly 5 h later. She was maintained on 8 mg
AdoCbl intramuscularly/d for 9 d. Other treatments remained unaltered throughout the study. Plasma and erythrocyte cobalamin levels before AdoCbl therapy were 338 and 170 ng/L, respectively (free B,z binding capacity 3409 ng/L) (normal values are 190-700, 105-230, and 1200-2000 ng/L, respectively). During administration of AdoCbl, concentrations rose maximally to >9000 ng/L in plasma and 2879 ng/L in erythrocytes (free B,z binding capacity 780 ng/L). There were substantial concentrations of AdoCbl in her erythrocytes, although the individual cobalamins were not quantified separately. However, although urinary methylcitrate concentrations fell slightly for a short period, urinary methylmalonate concentrations rose (Fig. I) and there was no significant biochemical (or clinical) response to AdoCbl therapy.
Further studies on fibroblasts from patient 11. The lack of response in vivo to AdoCbl therapy despite normalization of mutase activities in cell sonicates by addition of cofactor prompted further studies of cells from patient I I. Propionate incorporation studies were camed out in the presence of saturating concentrations of AdoCbl during the 18-h incubation in cells from patients 11 and 10 and from mut0 patients. Results (Table  3) showed that although control cell lines showed a marked increase in propionate incorporation under these conditions (compare Table 2 ) and cells from patient 10 showed supranormal activity, cells from patient 1 1 (and mut0 patients) showed no increase in propionate incorporation.
DISCUSSION
These results show that a detailed classification of (cell lines from) patients with methylmalonic aciduria may be made on the basis of direct methylmalonyl CoA mutase activity combined with propionate incorporation studies with and without the addition of cobalamin cofactors. The mutase assay used has also been used for the analysis of amniocytes and fetal fibroblasts and is suitable for direct assay of mutase activity in chorionic villus tissue. The majority of patients studied were classified as mut0 variants, with no detectable mutase activity in the presence of saturating cofactor concentrations. One patient could be classified as a mut-variant but was unresponsive to cobalamin therapy in vivo. Two patients were classified as Cbl variants, one as a Cbl A variant responsive to hydroxocobalamin therapy in vivo and in vitro and one as a Cbl B variant. This latter patient (patient 11) was unresponsive to OHCbl therapy during her initial management after diagnosis and during the present study also failed to respond in vivo to AdoCbl therapy, despite the ability of her cell sonicates to show normal mutase activity in the presence of added cofactor. The results of studies of propionate incorporation in the presence of saturating concentrations of AdoCbl suggest that this cofactor is unable to enter the cells in an unchanged form and is probably hydrolyzed on uptake into the cells to OHCbl. Cells from patient 10 were responsive to both OHCbl and AdoCbl, lending support to this hypothesis. Conversion of AdoCbl to OHCbl by light irradiation was excluded because all studies with added cofactor were camed out in the dark.
These observations are consistent with the results reported by
Batshaw et al. (7) of a trial with adenosylcobalamin in a Cbl B patient when there was no sustained response to cofactor therapy. These authors concluded that the adenosylcobalamin did not reach the mitochondria in an intact form or that an abnormality of intramitochondrial compartmentalization or enzyme interaction prevented adequate access and binding of AdoCbl to the mutant apoenzyme. The results from studies of cells from our patient tend to exclude the latter, because normal mutase activity could be achieved in cell sonicates, and add support to the former conclusion. The apparent response to OHCbl or even to cyanocobalamin of some patients classified as Cbl B mutants on the basis of complementation studies indicates the inability of complementation to delineate all the molecular variants leading to methylmalonic aciduria. Some of these patients may well have mutations affecting the activity or cofactor binding of deoxyadenosyltransferase that may be sufficiently enhanced by phar- * n = 3 lines, studied in duplicate; values are medians. All cultures a n d assays were carried o u t in the dark.
macologic doses of hydroxocobalamin rather than a total deficiency of enzyme activity; cells from such variants would not show complementation with cells from patients with total enzyme deficiency and all would be classified as "Cbl B" mutants.
Our observations suggest that the minority of Cbl B patients who are responsive to OHCbl have a different molecular defect from unresponsive patients that may be revealed by further study. Our results have shown that it is unlikely that AdoCbl reaches the mitochondria in an intact form and that therapy with this form of the cofactor offers no advantage over the use of hydroxocobalamin in the treatment of patients with methylmalonic aciduria.
The results reported briefly by Bhatt et al. (8) in a biochemically unclassified patient without detail of the urinary methylmalonate concentrations after treatment are difficult to interpret but suggest that this patient was in fact a mutase-deficient patient and that perhaps the methods used for monitoring were inadequate. The reported transient response to OHCbl is not uncommon in patients with methylmalonyl CoA mutase deficiencies and such brief, uncorroborated reports need to be treated with care.
